Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through our AI-enabled biomarker platform, we combine rich sources of information on patients’ brain activity and behavior to rapidly develop highly-effective medicines for targeted populations. We aim to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.
Alto was founded in 2019 by Amit Etkin, MD, PhD. As a Professor of Psychiatry at Stanford, Dr. Etkin was dismayed by the lack of innovation in the treatment of mental health conditions across decades. Psychiatry to this day still operates through a trial-and-error approach.
Total Funding: $40,000,000
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2019
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Alto Neuroscience
